Observational studyOpen heart2021
Natural course of tricuspid regurgitation and prognostic implications.
Observational study in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Bibliometric analysis of imaging and treatment strategies for severe tricuspid regurgitation from 2015 to 2023.Frontiers in cardiovascular medicine · 2024Pooled it
- Biomarkers of systemic disease burden and outcomes after transcatheter tricuspid edge-to-edge repair.BMC cardiovascular disorders · 2026Article
- Integrating Biomarkers and Hemodynamics for 1-Year Mortality Risk Stratification in Transcatheter Tricuspid Intervention.CJC open · 2026Article
- Comparative prognostic performance of risk scores for 12-month mortality and rehospitalization after transcatheter tricuspid valve intervention.Annals of cardiothoracic surgery · 2026Article
- 2025 ESC/EACTS valvular heart disease guidelines: practical updates on mitral and tricuspid regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Short-term outcomes of commercial transcatheter tricuspid valve intervention: a systematic review and meta-analysis.Annals of cardiothoracic surgery · 2026Article
- Revisiting tricuspid regurgitation: Historical insights and emerging research perspectives.European journal of clinical investigation · 2026Review
- Real-World Clinical Outcomes and Health Care Utilization in Patients With Severe Tricuspid Regurgitation.Structural heart : the journal of the Heart Team · 2025Article
- Time to assess more than prognosis: advancements and challenges in transcatheter tricuspid valve interventions.Frontiers in cardiovascular medicine · 2024Review
- Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure-A Prospective Observational Study.Journal of clinical medicine · 2023Article
- Effect of Telehealth Services on Mitral and Tricuspid Regurgitation Progression: Retrospective Study.Journal of medical Internet research · 2023Article
- Association Between Functional Tricuspid Regurgitation and Mortality Following Cardiac Surgery.JACC. Advances · 2023Article
- Echocardiography Imaging of the Right Ventricle: Focus on Three-Dimensional Echocardiography.Diagnostics (Basel, Switzerland) · 2023Review
- Transvenous ICD Implantation into a Coronary Sinus Branch: A Safe and Feasible Alternative to Deliver ICD after Tricuspid Valve Reconstruction.Case reports in cardiology · 2023Article
- Progression of Chronic Kidney Disease and All-Cause Mortality in Patients with Tricuspid Regurgitation.Diseases (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFunctional tricuspid regurgitation (TR) is a frequent finding in echocardiography. Literature suggests significant TR is associated with poor prognosis. Still, data remain limited. This study aimed to evaluate long-term prognostic implications in patients with TR.
methodsIn this observational cohort study, data from 1650 consecutive patients were analysed. Primary endpoint was all-cause mortality. Mean follow-up time was 1090 days. TR grades at baseline and follow-up were compared. Survival analyses were performed to identify prognostic factors.
resultsAt baseline, 14.1% patients showed no, 63.8% mild, 17.4% moderate and 4.7% severe TR. 359 patients (21.8%) died within the study period. TR at baseline was associated with excess mortality. Moderate and severe TR were of prognostic implication in all subgroups irrespective of systolic pulmonary artery pressure (sPAP) (</≥40 mm Hg) and left ventricular ejection fraction (LV-EF) (</≥50%). Survival was worst in patients with moderate and severe TR and concomitant elevated sPAP or reduced LV-EF at 1 and 3 years, respectively (p<0.001; p<0.001). In a multivariate model, including cardiac and non-cardiac risk factors, moderate and severe TR, sPAP and impaired right ventricular (RV) function were independent predictors for survival (HR 1.89, CI 1.07 to 3.36, p=0.029; HR 2.93, CI 1.57 to 5.49, p=0.001; HR 1.44, CI 1.25 to 1.65, p<0.001; HR 1.43, CI 1.14 to 1.79, p=0.002). Overall progression of TR on follow-up was 28.4%. Patients with TR progression showed significantly worse survival (HR 1.44, CI 1.11 to 1.81; p=0.006).
conclusionWhile TR progressed over time, it was associated with impaired long-term survival. TR grade, RV dysfunction, sPAP and TR progression were independent predictors for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.